Spoken Alpha
Vistagen Therapeutics, Inc.
Vistagen Therapeutics develops intranasal pherine product candidates that activate nasal chemosensory neurons to treat neuropsychiatric and women's health disorders without systemic absorption.
Vistagen Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $10.2M market cap.
VTGN missed consensus EPS by 0.0% in Q1 FY2027, reported Aug 13, 2026.
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VTGN.
$ curl https://api.spokenalpha.com/v1/companies/VTGNFAQ
Spoken Alpha indexes VTGN's earnings call transcripts at https://spokenalpha.com/companies/VTGN. Each call links to attributed speakers and parsed analyst Q&A. Vistagen Therapeutics, Inc.'s own investor relations page is at https://www.vistagen.com/investors/overview.
Vistagen Therapeutics, Inc. (VTGN) held its most recent earnings call on 2025-11-13, covering fiscal Q2 2026.
Vistagen Therapeutics, Inc. (VTGN) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2027 | 2026-08-13 | $-0.30 | $-0.29 | -3.5% | $1.5M | — | — | EODHD |
| Q4 FY2026 | 2026-06-14 | $-0.37 | $-0.42 | +11.9% | $465.0K | — | — | EODHD |
| Q3 FY2026 | 2026-02-11 | $-0.45 | $-0.48 | +6.3% | $303.0K | — | — | EODHD |
| Q2 FY2026 | 2025-11-12 | $-0.54 | $-0.44 | -22.7% | $258.0K | — | — | EODHD |
| Q1 FY2026 | 2025-08-06 | $-0.47 | $-0.47 | 0.0% | $244.0K | — | — | EODHD |
| Q4 FY2025 | 2025-06-16 | $-0.44 | $-0.85 | +48.2% | $-15.0K | — | — | EODHD |
| Q3 FY2025 | 2025-02-12 | $-0.46 | $-0.52 | +11.5% | $234.0K | — | — | EODHD |
| Q2 FY2025 | 2024-11-06 | $-0.42 | $-0.39 | -7.7% | $183.0K | — | — | EODHD |
| Q1 FY2025 | 2024-08-12 | $-0.35 | $-0.40 | +12.5% | $84.0K | — | — | EODHD |
| Q4 FY2024 | 2024-06-10 | $-0.25 | $-0.36 | +30.6% | $197.3K | — | — | EODHD |
| Q3 FY2024 | 2024-02-12 | $-0.22 | $-0.27 | +18.5% | $411.4K | — | — | EODHD |
| Q2 FY2024 | 2023-11-08 | $-0.66 | $-0.68 | +2.9% | $278.0K | — | — | EODHD |
| Q1 FY2024 | 2023-08-09 | $-0.94 | $-0.86 | -9.3% | $177.0K | — | — | EODHD |
| Q4 FY2023 | 2023-06-27 | $-1.75 | $-1.50 | -16.7% | $175.6K | — | — | EODHD |
| Q3 FY2023 | 2023-02-06 | $-1.50 | $-1.80 | +16.7% | $179.6K | — | — | EODHD |
| Q2 FY2023 | 2022-11-09 | $-2.40 | $-0.60 | -100.0% | $-892.5K | — | — | EODHD |
| Q1 FY2023 | 2022-08-10 | $-3.00 | $-2.25 | -33.3% | $310.1K | — | — | EODHD |
| Q4 FY2022 | 2022-06-22 | $-0.09 | $-0.06 | -50.0% | $38.9K | — | — | EODHD |
| Q3 FY2022 | 2022-02-09 | $-1.50 | $-2.25 | +33.3% | $357.9K | — | — | EODHD |
| Q2 FY2022 | 2021-11-09 | $-2.10 | $-2.25 | +6.7% | $358.0K | — | — | EODHD |
Source: EODHD. VTGN reported actuals as published; sparse fields render as —.